X4 Pharmaceuticals Gains Buy Rating With $12 Target and $240M Cash Raise
Guggenheim initiated coverage of X4 Pharmaceuticals with a Buy rating and $12 price target, implying 200% upside from $3.97. X4 raised $240.3 million, extending its cash runway into 2028, and expects to finish 4WARD Phase 3 enrollment by Q3 2026 for a U.S. chronic neutropenia market of 15,000 patients.
1. Guggenheim Initiation and Price Target
Guggenheim launched coverage with a Buy rating on X4 Pharmaceuticals and assigned a $12 price target, implying roughly 200% upside from the current $3.97 share price. The firm cited X4’s differentiated hematology focus on mavorixafor as a key value driver.
2. Cash Raise and Financial Runway
X4 Pharmaceuticals completed two financings totaling $240.3 million in gross proceeds, extending its cash runway through the end of 2028 and supporting ongoing Phase 3 development. The bolstered balance sheet reduces near-term funding risk for its clinical programs.
3. 4WARD Phase 3 Trial and Market Potential
The 4WARD pivotal Phase 3 trial for primary chronic neutropenia targets enrollment completion by Q3 2026, addressing an estimated 15,000-patient U.S. market. Mavorixafor, an oral CXCR4 antagonist, is positioned as a potential first-in-class therapy in this underserved indication.